Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Paying $37.5M for Varian's ICP-MS, Lab GC, GC-QQQ-MS Businesses


This story originally ran on March 15.

Bruker is paying $37.5 million for three Varian businesses as part of that company’s acquisition by Agilent Technologies, Bruker disclosed in a document filed with the US Securities and Exchange Commission last week.

As part of Agilent’s $1.5 billion acquisition of Varian, the two firms were required by the European Commission to divest a number of businesses [See PM 01/22/10].

Last week, Bruker and Agilent announced that Bruker would be purchasing certain Varian product lines including its inductively coupled plasma mass spectrometers, laboratory GC instruments, and GC triple-quadrupole mass specs. The firms also said that they intend to enter into a transitional services agreement and a supply agreement to continue the uninterrupted delivery of products and services to current and new customers of the three businesses.

The sale to Bruker of the businesses is expected to close by April 30. In its SEC document, Bruker further added that if the deal does not close by July 25 —extendible to Aug. 24 under certain conditions — either party can terminate the transaction without penalty.

Bruker also said that it will offer employment to “the majority” of employees of the three businesses.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.